Humacyte’s Symvess: A Promising Solution for Hemodialysis Challenges with Buy Rating

Analyst Josh Jennings from TD Cowen reiterated a Buy rating on Humacyte (HUMA – Research Report) and keeping the price target at $5.00.

Josh Jennings has given his Buy rating due to a combination of factors related to Humacyte’s promising developments in the AV Access indication for their bioengineered vessel, Symvess. The recent discussions with Humacyte’s management have highlighted the potential of their product to address significant unmet needs in the hemodialysis patient population, where current solutions often fail.
Humacyte’s approach targets a large and underserved market, as existing arteriovenous fistulas frequently do not mature properly, leading to reliance on less effective alternatives. The company’s vessel offers a biologically compatible option that reduces infection risks and hospitalizations, making it a compelling choice for patients with historically poor outcomes. This strategic focus, alongside a clear path to regulatory approval, supports the Buy rating.

Jennings covers the Healthcare sector, focusing on stocks such as Abbott Laboratories, Medtronic, and TransMedics Group. According to TipRanks, Jennings has an average return of 3.8% and a 52.52% success rate on recommended stocks.